U.S. Personal Products Stock News

Rosen Law Firm has opened an investigation into DNOW (NYSE:DNOW) for potential securities law violations. The investigation follows disappointing fourth quarter financial results and a material decline in DNOW's share price. Shareholders are being contacted regarding possible class action claims related to allegedly misleading business information. DNOW supplies products and services to industrial and energy markets, so its results are often closely tied to trends in capital spending and...

Ryerson Holding (RYZ) is back on investors’ radar after recent trading moves highlighted its mix of positive long term returns and current loss making results, with value metrics drawing closer attention. See our latest analysis for Ryerson Holding. At a share price of US$28.07, Ryerson Holding’s recent 1 month share price return of 7.01% and 1 year total shareholder return of 32.01% point to building momentum after a weaker 3 year total shareholder return. If you are weighing Ryerson against...

Nvidia’s CEO used the Computex stage to outline plans for ongoing AI chip development and large scale production. The comments pointed to sustained demand for AI-focused semiconductors and related manufacturing capacity. These signals are relevant for semiconductor equipment suppliers such as Nova (NasdaqGS:NVMI), which serve metrology and process control needs in chip fabrication. Nova operates in the semiconductor equipment space, supplying metrology and process control tools that help...

BioNTech overview and recent share performance BioNTech (BNTX) has stayed in focus for investors as its share price closed at US$88.45, with the stock down over the past month and past 3 months and weaker over the past year. See our latest analysis for BioNTech. With the share price down 10.97% over the past month and the 1-year total shareholder return declining 20.42%, recent weakness suggests momentum has been fading rather than building for BioNTech. If you are looking beyond BioNTech in...

Anyone interested in CMS Energy Corporation ( NYSE:CMS ) should probably be aware that the Senior Vice President of...

The recent 15% drop in Orion Energy Systems, Inc.'s ( NASDAQ:OESX ) stock could come as a blow to insiders who...

Salesforce, Inc. ( NYSE:CRM ) recently posted some strong earnings, and the market responded positively. We have done...

Some Ryder System, Inc. ( NYSE:R ) shareholders may be a little concerned to see that the Executive VP, Robert Fatovic...

Centene (CNC) is back in focus after reporting Q1 2026 results that topped expectations and after securing multi-year Medicaid and Medicare related contracts in Nevada, Iowa, and Mississippi, prompting fresh attention on the stock’s setup. See our latest analysis for Centene. The Q1 beat and fresh state contract wins come on top of strong recent share price momentum, with a 30 day share price return of 11.18% and a 90 day gain of 37.62%, even as the 5 year total shareholder return is down...

Weatherford International (NasdaqGS:WFRD) plans to redomesticate from Ireland to the United States. The company has signed a definitive agreement to acquire NCS Multistage Holdings. Both corporate actions are aimed at reshaping Weatherford's operational structure and completions portfolio. For investors following NasdaqGS:WFRD, these moves come after a period of strong share price performance, with the stock up 28.7% year to date and 126.3% over the past year, based on a recent close of...

Talen Energy (NasdaqGS:TLN) has received all remaining regulatory approvals for its planned acquisition of three power generation assets in Indiana and Ohio. The cleared transaction covers the Lawrenceburg Power Plant, Waterford Energy Center and Darby Generating Station. The company expects the deal to close in the coming weeks, subject to completion of remaining transaction steps. Talen Energy now approaches this deal with a share price of $379.59 and a very large 3 year return, around...

In the past few days, Stagwell reported strong Q4 and full-year 2025 results, highlighting growth in its digital transformation and Marketing Cloud segments, alongside an announced US$400 million share repurchase program focused on returning capital to investors. Together with an intensified push into AI-powered marketing services, these moves underscore how Stagwell is trying to position itself as a technology-centered challenger in the global advertising and communications industry. Next,...

Recent performance snapshot PVH (PVH) has drawn fresh attention after a strong run in its stock, with the price around $98 and gains of 11% over the past month and 49% over the past 3 months. See our latest analysis for PVH. The sharp 49.3% 3 month share price return sits alongside a 44.5% year to date share price gain. At the same time, the 1 year total shareholder return of 21.5% points to momentum that has been building rather than fading. If PVH’s recent run has you thinking about what...

If you are wondering whether TTM Technologies at US$189.60 is priced for strength or stretched too far, the next sections will focus squarely on what the current share price implies about value. The stock has been volatile lately, with a small decline of 0.6% over the last week but a 20.4% gain over 30 days, while returns year to date are 168.5% and the 3 year and 5 year returns are both well into double digit multiples. Recent coverage has focused on TTM Technologies as a fast moving tech...

Event context and recent stock move BioMarin Pharmaceutical (BMRN) has drawn investor attention after recent trading, with the stock up about 2.5% on the day and 4.4% over the past week, while longer term returns remain weaker. See our latest analysis for BioMarin Pharmaceutical. The latest move sits against a mixed backdrop, with the share price down about 10% over the past three months and year to date, while the 1-year total shareholder return is also slightly negative. This pattern...

Why Public Service Enterprise Group is on investors’ radar today Public Service Enterprise Group (PEG) has moved lower recently, with the stock down about 3% over the past month and around 7% in the past 3 months, prompting a closer look at its current setup. See our latest analysis for Public Service Enterprise Group. At a share price of $77.75, PEG’s recent pullback, including a 30-day share price return of down 3.36% and a 90-day move of down 7.35%, contrasts with its 3-year total...

In early June 2026, MasTec drew attention as valuation services flagged the stock as significantly overvalued and insider sales reached about US$3.5 million over three months with no offsetting insider purchases. This combination of valuation concerns and insider activity has sharpened investor focus on how MasTec’s growth opportunities in grid, data center, and clean energy projects balance against perceived risk. We’ll now examine how insider selling alongside strong infrastructure demand...

Krystal Biotech (KRYS) shares moved after the company reported first quarter 2026 results, with earnings per share above estimates and revenue growth tied to strong Vyjuvek uptake, and reaffirmed expense guidance. See our latest analysis for Krystal Biotech. The stock has built solid momentum over the past year, with a 1-year total shareholder return of 128.6% and a year to date share price return of 22.24%. The latest 1-day move of 2.94% after earnings suggests investors are reassessing...

Wondering whether American Homes 4 Rent is fairly priced or offering hidden value at current levels? This article walks through the key clues in the valuation data so you can judge for yourself. The stock recently closed at US$32.24, with returns of 0.5% over the past week, 0.8% over the past month, a 1.0% gain year to date, but a decline of 10.0% over the past year and 5.5% over five years. Recent coverage has focused on American Homes 4 Rent as part of broader conversations about listed...

PBF Energy has recently completed a US$500 million senior, unsecured, unsubordinated fixed‑rate bond offering, issuing 7.25% notes due June 1, 2034 under Regulation S and Rule 144A. This sizeable debt raise highlights how PBF is accessing credit markets to support its balance sheet flexibility and longer-term funding needs. We’ll now assess how the new US$500 million senior notes may influence PBF Energy’s investment narrative and future risk-reward profile. This technology could replace...

The Morning Bull - US Market Morning Update Thursday, Jun, 4 2026 US stock futures are slightly softer this morning, with key contracts such as the S&P 500 mini down around 0.1%, as investors weigh weaker global growth signals against stronger pockets of demand. The OECD now sees global growth at 2.8% in 2026 and around 2.0% for the US. In plain terms, this suggests a cooler but still growing world economy. At the same time, oil data show US crude inventories falling by 6.8 million barrels,...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) has announced a new collaboration with AI firm Inceptive Nucleics focused on accelerating RNAi drug discovery. The partnership will apply generative AI models to RNAi drug design with the goal of improving research productivity and speed for new therapeutics. This AI collaboration is positioned as an important step in advancing Alnylam's Alnylam 2030 strategy. For investors tracking Alnylam Pharmaceuticals at a share price of $292.58, this AI...

Wondering if Ollie's Bargain Outlet Holdings at around US$79.74 is a bargain or a value trap? This article breaks down what the current price might actually be telling you. The stock is up 1.4% over the past week, although it is down 3.3% over the past month, 28.4% year to date and 30.3% over the last year, which can change how investors think about both its potential and its risk. These moves come as investors continue to weigh the broader outlook for off price retailers and...

Agios Pharmaceuticals (AGIO) stock is in focus after the company signed an exclusive global licensing agreement with Oscotec for cevidoplenib, an oral SYK inhibitor targeting immune thrombocytopenia and other potential indications. See our latest analysis for Agios Pharmaceuticals. The cevidoplenib deal lands at a time when the share price is US$27.68, with a 1-day share price return of 4.41% but a 1-year total shareholder return that has fallen 18.66%. This suggests that recent momentum has...